Scienture Holdings, Inc. announced that it is commercializing Arbli™, a product which is a formulation of losartan potassium.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Scienture Holdings, Inc. announced that it is commercializing Arbli™, a product which is a formulation of losartan potassium.
Coverage
Newest first; wire copies grouped- GlobeNewswireSCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercializati